Search research articles
Contact Us
Filters
Showing results (161-170 of 191) with videos related to
Page
of 20
Sort By:
Cancer Research Communications
|
June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Rahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
European Urology
|
October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder
Amanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida, Andrew W Hahn, Neal Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
The Prostate
|
April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer
Elisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
The Journal of Urology
|
September 3, 2024
Reply by Authors
Neal Shore, Christopher Pieczonka, Sean Heron, et al.
JAMA Oncology
|
February 9, 2023
Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial
Neil F Mariados, Peter F Orio, Zvi Schiffman, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 191) with videos related to
Sort By:
Page
of 20
Cancer Research Communications
|
June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Rahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
European Urology
|
October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder
Amanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial
Joaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida, Andrew W Hahn, Neal Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
The Prostate
|
April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer
Elisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
The Journal of Urology
|
September 3, 2024
Reply by Authors
Neal Shore, Christopher Pieczonka, Sean Heron, et al.
JAMA Oncology
|
February 9, 2023
Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial
Neil F Mariados, Peter F Orio, Zvi Schiffman, et al.
Page
of 20